Related Experiment Videos
Neonatal manifestations of maternal phencyclidine (PCP) abuse
Insights
Maternal phencyclidine (PCP) use during pregnancy can cause neonatal symptoms like jitteriness and hypertonicity. Urinalysis confirmed PCP in infants, who improved with phenobarbital but showed persistent symptoms, suggesting potential long-term effects.
Area of Science:
- Neonatal Abstinence Syndrome
- Developmental Toxicology
- Pharmacology
Background:
- Maternal phencyclidine (PCP) abuse during pregnancy presents a potential risk to newborns.
- Understanding neonatal outcomes associated with prenatal PCP exposure is crucial for clinical management.
Observation:
- Two cases of neonates born to mothers with documented phencyclidine use during pregnancy were analyzed.
- Observed neonatal symptoms included jitteriness, hypertonicity, vomiting, and diarrhea.
- Phencyclidine was detected in both infants' urine within the first few days of life.
Findings:
- Neonatal symptoms associated with maternal PCP abuse are clinically similar to narcotic withdrawal syndrome.
- Phenobarbital treatment provided initial symptomatic relief, but jitteriness and hypertonicity persisted post-therapy.
- One infant exhibited microcephaly, raising concerns about potential teratogenic effects of PCP.
Implications:
- Urinalysis is a key diagnostic tool for confirming PCP exposure in neonates.
- The teratogenicity of phencyclidine requires further investigation.
- Additional research is needed to clarify the metabolism and optimal treatment strategies for neonatal PCP exposure.
Abstract:
Two cases concerning newborn infants whose mothers used phencyclidine (PCP) during pregnancy are described. The neonatal symptoms of maternal PCP abuse were jitteriness, hypertonicity, vomiting, and one case of diarrhea. In both infants, PCP was detected in the urine during the first few days of life. Both infants were successfully treated with phenobarbital but they continued to remain jittery and slightly hypertonic following discontinuation of the therapy. In one case the infant was noted to be microcephalic. In the neonate, the symptoms of maternal PCP abuse are similar to the symptoms of narcotic withdrawal. The diagnosis of PCP effects in the neonate can be confirmed by urinalysis for the drug. The teratogenicity of PCP remains a possibility. The metabolism and treatment of PCP effects in the newborn need further clarification.